Log in to save to my catalogue

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2025801116

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

The addition of pembrolizumab to chemotherapy for metastatic lung cancer without
EGFR
or
ALK
mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.

Alternative Titles

Full title

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2025801116

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2025801116

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1801005

How to access this item